SBRT vs IMRT: Prostate Cancer Bowel Toxicity Study
- Here's a breakdown of the key findings from the provided text, focusing on the comparison between Stereotactic body radiation Therapy (SBRT) and moderately hypofractionated Intensity-Modulated Radiation Therapy (IMRT)...
- * Disease-Free survival (DFS): SBRT had an 89% 5-year DFS rate vs.
- The investigators concluded that SBRT is safe for treating intermediate-risk prostate cancer.
Here’s a breakdown of the key findings from the provided text, focusing on the comparison between Stereotactic body radiation Therapy (SBRT) and moderately hypofractionated Intensity-Modulated Radiation Therapy (IMRT) for intermediate-risk prostate cancer:
Key Findings:
* Disease-Free survival (DFS): SBRT had an 89% 5-year DFS rate vs. 92% with IMRT. While slightly lower,it didn’t cross the futility bound,suggesting SBRT wasn’t definitively worse.
* Biochemical Failure: SBRT showed a higher 3-year biochemical failure rate (8%) compared to IMRT (4%), which was statistically significant (P = .037).
* Overall Survival (OS): No significant difference in 5-year OS rates between SBRT (91%) and IMRT (94%) (P = .66).
* Bowel Quality of Life: SBRT was associated with worse bowel quality of life. 35% experienced a minimal clinically important difference (MCID) with SBRT vs. 44% with IMRT (P = .034). Longitudinal analysis showed a significant difference favoring IMRT (+2.68, P = .0016).
* Urinary Quality of life: SBRT showed improvements in patient-reported urinary incontinence-related quality of life compared to IMRT. Fewer patients receiving SBRT experienced MCID in urinary incontinence at 2 years.
* Toxicity: Overall urinary toxicity was not significantly different between the two treatments.
* Rectal Toxicity: The NRG GU-005 trial did meet its primary endpoint of decreasing rectal toxicity with SBRT compared to IMRT. (This is a key takeaway).
overall Conclusion:
The investigators concluded that SBRT is safe for treating intermediate-risk prostate cancer. The study highlights a trade-off: SBRT appears to reduce rectal toxicity (a primary goal of the trial) but may worsen bowel quality of life and increase the risk of biochemical failure.It also showed benefits for urinary incontinence-related quality of life.
Additional Facts:
* Conference: The findings were presented at the 2025 American Society for Radiation Oncology Annual Meeting. (https://www.cancernetwork.com/conference/astro)
* Study Author: rodney J. Ellis, MD, university of Southern Florida Health and Tampa general Hospital.
* Rectal Spacer: the use of a rectal spacer was noted as contributing to the significant reduction in rectal toxicity.